ArticleEye and vision (London, England)2026
Variation in corneal biomechanical properties following continuous cross-linking treatment.
Article in Eye and vision (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundThis retrospective study aimed to evaluate the efficacy of transepithelial accelerated corneal cross-linking (transEpi ACXL) when applied separately or combined with phototherapeutic keratectomy (transPTK ACXL) in keratoconic eyes using biomechanical parameters.
methodsThe study included eyes with progressive keratoconus treated with either continuous transEpi ACXL or transPTK ACXL with 6 months follow-up. The following parameters were assessed preoperatively and 6 months postoperatively: biomechanically corrected intraocular pressure (bIOP), maximum and mean keratometry (K
resultsA total of 75 eyes from 72 patients were included (31 in the transEpi ACXL group and 44 in the transPTK ACXL group). The two groups were comparable in age (23.0 ± 5.0 vs. 21.3 ± 5.2 years) and TKC grade distribution (grades 1-4), with no statistically significant between-group differences (P = 0.321 and 0.766, respectively). Both groups exhibited significant reductions in IIR, and increases in SSIv1 and SSIv2 (all P < 0.05). The improvements in K
conclusionsTransPTK ACXL resulted in better biomechanical and visual benefits in comparison with transEpi ACXL 6 months after treatment. SSIv2 demonstrated superior performance in assessing the efficacy of corneal cross-linking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.